Table 3.
The treatment measures and complications of patients with COVID-19.
| Total (n = 317) | Survivor (n = 269) | Dead (n = 48) | p-Value | |
|---|---|---|---|---|
| Treatment measures | ||||
| Antivirals | 301 (95.0) | 253 (94.1) | 48 (100) | .083 |
| Glucocorticoids | 101 (31.9) | 61 (22.7) | 40 (83.3) | <.001 |
| Immunoglobulin | 118 (37.2) | 76 (28.3) | 42 (87.5) | <.001 |
| Thymosin | 68 (21.5) | 43 (16.0) | 25 (52.1) | <.001 |
| Ammonium glycyrrhizinate | 46 (14.5) | 32 (11.9) | 14 (29.2) | .003 |
| Atomization inhalation | 71 (22.4) | 62 (23.0) | 9 (18.8) | .511 |
| Respiratory support | ||||
| Nasal cannula or mask | 303 (95.6) | 255 (94.8) | 48 (100) | .106 |
| NIMV | 79 (24.9) | 31 (11.5) | 48 (100) | <.001 |
| IMV | 67 (21.1) | 19 (7.1) | 48 (100) | <.001 |
| Clinical outcomes | ||||
| Cardiac injury | 44 (13.9) | 16 (5.9) | 28 (58.3) | <.001 |
| Kidney injury | 47 (14.8) | 30 (11.2) | 17 (35.4) | <.001 |
| Liver injury | 144 (45.4) | 118 (43.9） | 26 (54.2) | .187 |
| Hospital stay | 22 (13–29) | |||
| Survival day | 19 (10–27) |
Note. Continuous variables were expressed as median (P25–P75); categorical variables were expressed as number (%).
Abbreviations. P25–P75, percentile 25 to percentile 75; NIMV, noninvasive mechanical ventilation; IMV, invasive mechanical ventilation.
Statistically significant differences between groups are marked in bold.